MSF Access

01/09/2026

The current Ebola disease outbreak caused by the Bundibugyo virus in the Democratic Republic of the Congo has disproportionately affected children.

In a commentary published in The Lancet today, MSF calls for urgent action from all stakeholders involved in research on Bundibugyo virus treatment and prevention to ensure that children are meaningfully included in planned, evidence-generating research on medical countermeasures, and, in particular, have timely access to paediatric formulations for ongoing trials of oral post-exposure prophylaxis.

Children and pregnant women are known to be at high risk of death from Ebola virus disease.1,2 In the current outbreak of Bundibugyo virus in the Democratic Republic of the Congo, the inequality in outcomes is particularly stark for children. As of Aug 4, 2026, of 1124 deaths among people with confi...

21/08/2026

What is the global double standard in care? Authors from Voices in Action Diabetes outline the issue and explore possible solutions:

Newsletter Edition #374 [The Curated Primer] Subscribe Now! Readers, In today's edition, activists are calling for including insulin analogue pens as a first-line treatment option in the World Health Organization’s forthcoming guidelines for type 1 diabetes. Despite insulin being indispensable, th...

12/08/2026

🫁 Tuberculosis is one of the world's deadliest diseases. It is curable, but only half of all children with tuberculosis get diagnosed.

For Francisco, a child in Mozambique with drug-resistant tuberculosis, it took nine months, a period of malnutrition, and numerous trips to the hospital to get a diagnosis and begin treatment.

Francisco’s long road to diagnosis is common among children with TB, because laboratory tests are designed for adults — not for children.

Read our interview with a pediatrician on how tuberculosis treatment decision algorithms help diagnose children more effectively: https://msfaccess.org/how-tb-treatment-decision-algorithms-help-diagnose-children-paediatricians-experience?utm_source=facebook

05/08/2026

🤔 Testing, testing: what do you know about Ebola tests?

📩 ...and, take the opportunity to subscribe to our newsletter right before the August issue!

Ensuring sustainable, adapted, ready and available diagnostic capacity is critical for a quick response to disease outbreak, and in the current Ebola outbreak, this must be a priority.

30/07/2026

We are taking our demand directly to Gilead at the conference in Rio de Janeiro, Brazil - a country where people still can't access lenacapavir, even when they contributed to the clinical trials for this breakthrough drug.

Read more: www.instagram.com/p/DbThjxUH4gy/

29/07/2026

⬇️ Join our campaign. Tell Gilead to drop the price of lenacapavir and make it available to all.

The 26th International AIDS Society Conference starts today in Rio de Janeiro, Brazil. Gilead Sciences will be there presenting new research on lenacapavir, a twice-yearly HIV prevention injection that is nearly 100% effective.

Here's what they won't be talking about: Brazil, the country hosting this conference, still can't access lenacapavir for the people who need it. Communities in Brazil participated in the clinical trials that helped prove this drug works. Yet Gilead's pricing and supply decisions keep it out of reach in Brazil, as well as 25 other countries.

Gilead alone should not decide who gets lenacapavir and who doesn't.

Two shots. $40. Everywhere.
https://www.doctorswithoutborders.org/latest/campaigns/access-to-LEN

28/07/2026

It's and over a quarter of a million children are still acquiring chronic hepatitis B at birth each year, resulting in many premature deaths.

But this can be prevented👇

27/07/2026

Why is responding to an Ebola disease outbreak so challenging?
Beyond treating patients, responders must quickly diagnose cases, source essential supplies, and overcome logistical hurdles and often in resource-limited settings.

Join our Ebola disease webinar series: "Everything you need to know on diagnostics and supply, and why it's not easy."
📅 Tuesday, 28 July 2026
🕓 4:00 PM (KL/MNL) | 3:00 PM (BKK/JKT)

Speakers:
🔴 Sonjelle Shilton, Diagnostic Advisor, MSF Access
🔴 Antonio Martin, Head, Global Direct Procurement, MSF International
Moderator:
🔴Sinhye Ha, Regional Advisor for Asia Pacific, MSF Access

Have a question? Submit it when you register and we'll do our best to answer it live. Register now: https://tinyurl.com/3jcnhnve

08/07/2026

It's been 12 years since "PharmaGate", a scandal where pharmaceutical companies spent R6 million trying to stop South Africa from making medicines more affordable. The South African Government promised reform. It still hasn't happened.

Meanwhile, real people are paying the price. A cystic fibrosis patient had to go to court just to try to get an affordable version of a life-changing medicine. A TB drug remained expensive because of patents, even after cheaper generics were available elsewhere.

Reflecting on the painfully slow progress towards patent reform in South Africa, Candice Sehoma, Regional Advisor for Africa, Doctors Without Borders (MSF) Access, and Tendai Mafuma, Senior Legal Researcher at Section27, examine the government’s continued delay in amending the country’s patent laws despite repeated commitments to do so.

The question we should all be asking: Why is South Africa still waiting to fix the patent law that blocks affordable medicines ⁉️
Read the full op-ed: https://msfsa.me/4y36cvm

07/07/2026

Today, MSF called for the inclusion of analogue insulin pens to Kenya’s Social Health Authority (SHA) benefits package.

“Over the past few years, Kenya has taken important steps in the right direction by including analogue insulin pens in its Essential Medicines List and the National Clinical Guidelines for Diabetes Management,” said Dr Narine Danielyan, MSF Medical Coordinator in Kenya. “Now is the time to go the last mile and ensure these devices are available as part of the Social Health Authority benefits package so that more people in Kenya have access to the insulin delivery device that is most effective for their own clinical needs, in alignment with national guidelines.”

Learn more:

MSF proposal for inclusion of insulin analogue pens and pen needles into Kenyan Social Health Authority benefits package